Merlin Properties SOCIMI SA (A28ZT1) News

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units...

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences. William...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million...

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to...

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company...

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing...

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities